Psychiatric biomarker development needs greater standardization, earlier validation, and closer collaboration between laboratories, researchers, industry, and regulators if objective tests are to become clinically useful, according to a new consensus statement from the American College of Neuropsychopharmacology (ACNP).
Despite advances in neuroscience, few biomarkers for psychiatric disorders have progressed beyond exploratory research. Clinical trials still largely recruit patients according to symptoms rather than underlying biological mechanisms, partly because conditions such as depression and schizophrenia encompass substantial biological and clinical variation.
The ACNP roadmap proposes a framework for moving candidate biomarkers from discovery through analytical and clinical validation to regulatory acceptance and, ultimately, routine care. Potential approaches include blood and other fluid-based assays, genomic markers, electroencephalography, neuroimaging, digital measurements from smartphones and wearables, and combinations of several data types. Because psychiatric disorders involve complex interactions between biological and environmental factors, the authors suggest that combining complementary measurements may ultimately prove more informative than relying on a single marker.
For laboratories, analytical validation is identified as a critical step. Candidate tests must reliably measure their intended target, with performance characteristics such as sensitivity, specificity, precision, accuracy, and reproducibility established before results can be linked confidently to patient outcomes. The authors note that biomarkers are sometimes incorporated into clinical trials without sufficient analytical validation, limiting subsequent clinical interpretation and development.
Standardization across laboratories and research sites is another priority. Common data elements, reference assays, harmonized protocols, quality-control procedures, and device standards could make findings easier to reproduce and compare across studies. The roadmap also recommends earlier engagement with regulators and independent validation across different cohorts and populations.
Near-term applications are expected to center on identifying patients for clinical trials, predicting treatment response, measuring drug effects, and monitoring safety rather than replacing established clinical endpoints.
The longer-term goal is to establish laboratory and digital tools that can distinguish biologically meaningful patient subgroups and support more precise treatment decisions. However, the authors emphasize that validation alone will not guarantee clinical adoption: tests will also need to fit laboratory and healthcare workflows, demonstrate clinical utility, scale across different settings, and generate sufficient evidence to support reimbursement.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
